Login to Your Account



Post-Nasdaq Jump, Neostem Adding $35M In Public Offering

By Jennifer Boggs
Managing Editor

Friday, October 4, 2013

Two months after shares of Neostem Inc. made the leap to Nasdaq, the New York-based firm added some much-needed capital, raising $35 million to support its expanding cell therapy business, including a lead therapeutic candidate aimed at heart attack patients.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription